We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Aegerion Pharmaceuticals Prices Public Offering of Common Stock

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Aegerion Pharmaceuticals Prices Public Offering of Common Stock"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

The net proceeds to Aegerion from this offering are expected to be approximately $47.3 million, after deducting underwriting discounts and commissions. The offering is expected to close on June 19, 2012, subject to customary closing conditions.

Jefferies & Company, Inc. and J.P. Morgan Securities LLC are acting as joint book-running managers in the offering. Leerink Swann LLC, Canaccord Genuity Inc., and Needham & Company, LLC are acting as co-managers for the offering. Aegerion has granted the underwriters a 30-day option to purchase up to an aggregate of 510,000 additional shares of common stock. Aegerion anticipates using the net proceeds from the offering to fund activities directed at gaining approval of its New Drug Application submission with the U.S. Food and Drug Administration and Marketing Authorization Application submission with the European Medicines Agency for lomitapide as a potential treatment for homozygous familial hypercholesteremia (HoFH), pre-commercial and commercial activities related to launching lomitapide in the United States, the European Union, in each case, if approved, and in any other countries where lomitapide is approved as a treatment for HoFH, expansion of operations in certain countries, and advancement of the clinical development of lomitapide as a potential treatment for pediatric and adolescent patients with HoFH and of adult patients with familial chylomicronemia, with any remainder to fund working capital, capital expenditures and to be used for general corporate purposes.

The securities described above are being offered by Aegerion pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement related to the offering has been filed with the SEC. A final prospectus related to the offering will be filed with the SEC. The preliminary prospectus is available, and the final prospectus will be available, on the SEC's website at http://www.sec.gov . In addition, copies of the preliminary prospectus supplement and the final prospectus, when available, may be obtained from Jefferies & Company, Inc., Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com; or J.P. Morgan Securities LLC, c/o Broadridge Financial, 1155 Long Island Avenue, Edgewood, New York 11717 or by telephone at 1-866-803-9204.

This release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.